Analysts' Assessment of MEDP Stock – What You Need to Know

This morning we watched Medpace drop -2.4% to a price of $367.19 per share. The Large-Cap Biotechnology company is now trading -13.15% below its average target price of $422.8. Analysts have set target prices ranging from $340.0 to $480.0 per share for Medpace, and have given the stock an average rating of buy.

Medpace's short interest — meaning the percentage of the share float that is being shorted — is lower than average at 4.6%. The stock's short ratio is 3.62. The company's insiders own 18.16% of its outstanding shares, which indicates a strong alignment between management and shareholder interests.

Another number to watch is the company's rate of institutional share ownership, which now stands at 81.9%. In conclusion, we believe there is positive market sentiment regarding Medpace.

Institutions Invested in Medpace

Date Reported Holder Percentage Shares Value
2023-12-31 Vanguard Group Inc 8% 2,556,443 $938,700,311
2023-12-31 Blackrock Inc. 8% 2,418,056 $887,885,988
2024-03-31 Wasatch Advisors LP 3% 974,415 $357,795,446
2023-12-31 Invesco Ltd. 2% 723,238 $265,565,762
2023-12-31 Riverbridge Partners LLC 2% 683,943 $251,137,031
2023-12-31 State Street Corporation 2% 671,145 $246,437,734
2023-12-31 Geode Capital Management, LLC 2% 492,931 $180,999,335
2023-12-31 TD Asset Management, Inc 2% 467,041 $171,492,785
2023-12-31 Fuller & Thaler Asset Management Inc. 1% 444,738 $163,303,347
2023-12-31 Wellington Management Group, LLP 1% 414,568 $152,225,224
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.